Implantable Cardioverter-Defib... Note

Implantable Cardioverter-Defibrillators for Patients With an LVEF >35%

The implantable cardioverter-defibrillator (ICD) remains a cornerstone therapy for the prevention of sudden cardiac death. Randomized clinical trials have demonstrated a survival benefit with ICDs for primary prevention in patients with a left ventricular ejection fraction (LVEF) of 35% or less; therefore, professional guideline recommendations on ICDs are based on this LVEF cutoff. However, most individuals who experience a sudden cardiac arrest do not have significant left ventricular dysfunction. Admittedly, these LVEF cutoffs are arbitrary, and the risk of sudden cardiac death is not dichotomous.